Computational Assessment of GABA Receptor Modulation in PTSD (NCT06852469)

Usually NOT eligible if any of the following apply:

• Exclusion Criteria: Exclusion Criteria:
• Has uncontrolled, clinically significant neurologic (including seizure disorders), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality, which may impact the ability of the subject to participate or potentially confound the study results;
• Pregnancy (assessed by urine test at time of screening and prior to administration of study medication) or lactation;
• Lifetime history of a chronic psychotic disorder or bipolar disorder type I as assessed by MINI;
• Current moderate or severe substance use disorder as assessed by MINI;
• Positive urine toxicology (drugs of abuse as determined by a positive urine test) at screening and before drug administration. Subjects who screen positive for THC will be given an opportunity to be included in the event of a negative urine test 2 weeks later. THC is not infrequently used for medicinal purposes and, in California, is legal for recreational use. Subjects who are positive for THC will therefore not be excluded, but will be retested to ensure that THC is unlikely to be influencing results;
• Self-report or observable signs of drug or alcohol intoxication or withdrawal;
• Current benzodiazepine or opioid use; other psychotropic medications are allowed as long as they are at a stable dose for at least 2 weeks and do not exhibit an unsafe interaction with the study medication;
• Current or recent use of any medication deemed by the study physician (Dr. Howlett) to exhibit an unsafe interaction with lorazepam;
• Past intolerance (including allergic) to lorazepam or another benzodiazepine;
• Active suicidal ideation or otherwise considered at high suicidal risk by trained study staff using the C-SSRS;
• History of a traumatic brain injury (TBI) resulting in loss of consciousness for more than 30 minutes;